Analyst Consensus ?
ConsensusHold23 ratings
Bullish1356.5%
Neutral939.1%
Bearish14.4%
IDEXX Laboratories, Inc. · IDXX · FY2025 Q2 · Calendar Q3 2025
IDEXX growth broadens as diagnostics adoption offsets U.S. visit pressure
The call supports a constructive operating thesis: product adoption, pricing, and international expansion are offsetting U.S. visit pressure, but durability depends on continued placement growth, consumables utilization, and execution.
Reported Before market openNASDAQHealthcare
$39.97B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$3.63
Consensus $3.28
EPS surprise
+10.7%
Reported versus consensus
Reported revenue
$1.11B
Consensus $1.06B
Revenue surprise
+4.4%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
+27.5%
Event window
SPY move
+1.5%
Same window
Abnormal move
+26.0%
Stock minus SPY
Volume
6.0×
Versus trailing sessions
Subsequent drift
-6.3%
Up to 20 sessions
IDXXSPY benchmark
Ask FN2 about IDXX FY2025 Q2
Transcript, numbers and history already loaded
Why did IDXX rise 27.5% after beating EPS estimates in FY2025 Q2?What changed in IDXX's guidance and outlook in FY2025 Q2?Give me the bull and bear case for IDXX after FY2025 Q2 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
The latest analysis shows a stronger emphasis on rapid inVue Dx adoption, broader new-test activity, international expansion, and a higher placement objective, while U.S. visit weakness remains unresolved.
Guidance delta
Raised; management linked the improved outlook to instrument momentum, favorable foreign exchange, pricing, and international growth.
Key takeaways
- Management described strong growth led by premium instrument placements and international markets.
- New platforms and tests are intended to expand consumables and recurring revenue.
- U.S. clinic-visit pressure remains a counterweight to pricing and product momentum.
- The central question is whether adoption and international execution can sustain the growth trajectory.
Management priorities
- Scale inVue Dx placements and its consumables base
- Expand Cancer Dx internationally subject to regulatory approvals
- Broaden the diagnostic menu, including planned FNA capability
- Add commercial capacity in selected countries while continuing specialty-test rollout
Follow IDXX with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$506.67Previous close
$247Low
$637.65Average
$830High
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Oct 8, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Barclays | Overweight | Overweight | Maintain | Aug 11, 2026 |
| UBS | Neutral | Neutral | Maintain | Aug 5, 2026 |
| Citigroup | Neutral | Neutral | Maintain | Aug 5, 2026 |
| Stifel | Buy | Buy | Maintain | Mar 31, 2026 |
| Piper Sandler | Neutral | Neutral | Maintain | Feb 9, 2026 |
| BTIG | Buy | Buy | Maintain | Feb 3, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Nov 4, 2025 |
| JP Morgan | Overweight | Overweight | Maintain | Nov 4, 2025 |
| Leerink Partners | Outperform | Outperform | Maintain | Jul 17, 2025 |
| B of A Securities | Neutral | Neutral | Maintain | Apr 21, 2025 |
| Goldman Sachs | Buy | Buy | Maintain | Jan 17, 2024 |
| Atlantic Equities | Neutral | Overweight | Downgrade | Aug 2, 2023 |
| Credit Suisse | Outperform | Outperform | Maintain | Aug 13, 2021 |
| Guggenheim | Neutral | Buy | Downgrade | Jul 12, 2021 |
| Stifel Nicolaus | Buy | Buy | Maintain | Jul 22, 2019 |
| Canaccord Genuity | Buy | Buy | Maintain | May 2, 2019 |
| Bank of America | Buy | Buy | Maintain | Nov 2, 2018 |
| PiperJaffray | Overweight | Overweight | Maintain | Jan 16, 2018 |
| Aegis Capital | Sell | Sell | Maintain | Jun 1, 2017 |
| CL King | Neutral | Neutral | Maintain | Apr 1, 2016 |
| Raymond James | Market Perform | Outperform | Downgrade | Aug 28, 2015 |
| Feltl & Co. | Hold | Sell | Upgrade | Jul 23, 2015 |
| Bank oferica | Buy | Buy | Maintain | Apr 20, 2012 |
Named analyst price targets
Upside is calculated against the persisted previous close $506.67. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Barclays | Glen Santangelo | $710 | $595.76 | +40.1% | Aug 11, 2026 |
| UBS | Analyst unavailable | $620 | $559.86 | +22.4% | Jul 27, 2026 |
| UBS | Andrea Alfonso | $640 | $569.17 | +26.3% | Apr 28, 2026 |
| Piper Sandler | Analyst unavailable | $750 | $644.61 | +48.0% | Feb 9, 2026 |
| Barclays | Glen Santangelo | $800 | $642.94 | +57.9% | Feb 5, 2026 |
| UBS | Andrea Alfonso | $730 | $639.6 | +44.1% | Feb 3, 2026 |
| BTIG | Analyst unavailable | $800 | $639.6 | +57.9% | Feb 3, 2026 |
| Barclays | Glen Santangelo | $850 | $706.65 | +67.8% | Dec 8, 2025 |
| Morgan Stanley | Analyst unavailable | $805 | $721.04 | +58.9% | Nov 4, 2025 |
| UBS | Analyst unavailable | $750 | $722.94 | +48.0% | Nov 4, 2025 |
| BTIG | Analyst unavailable | $830 | $722.94 | +63.8% | Nov 4, 2025 |
| Jefferies | Keith Devas | $830 | $722.94 | +63.8% | Nov 4, 2025 |
| Leerink Partners | Analyst unavailable | $785 | $722.94 | +54.9% | Nov 3, 2025 |
| Stifel Nicolaus | Jonathan Block | $775 | $722.94 | +53.0% | Nov 3, 2025 |
| Stifel Nicolaus | Jonathan Block | $700 | $628.54 | +38.2% | Oct 31, 2025 |
| UBS | Andrea Alfonso | $720 | $638.89 | +42.1% | Oct 1, 2025 |
| Morgan Stanley | Analyst unavailable | $722 | $641.94 | +42.5% | Aug 5, 2025 |
| BTIG | Analyst unavailable | $785 | $641.94 | +54.9% | Aug 5, 2025 |
| Stifel Nicolaus | Analyst unavailable | $640 | $682.78 | +26.3% | Aug 4, 2025 |
| Stifel Nicolaus | Jonathan Block | $510 | $495.73 | +0.7% | Jun 24, 2024 |
| Barclays | Analyst unavailable | $590 | $507.68 | +16.4% | Feb 8, 2023 |
| J.P. Morgan | Analyst unavailable | $550 | $487.04 | +8.6% | Feb 7, 2023 |
| Atlantic Equities | Analyst unavailable | $600 | $485.53 | +18.4% | Feb 7, 2023 |
| Oppenheimer | Analyst unavailable | $247 | $483.2 | -51.3% | Feb 2, 2023 |
| Citigroup | Analyst unavailable | $268 | $483.2 | -47.1% | Feb 2, 2023 |
| Citigroup | Analyst unavailable | $273 | $420.63 | -46.1% | Dec 9, 2022 |
| Morgan Stanley | Analyst unavailable | $543 | $435.78 | +7.2% | Nov 15, 2022 |
| Stifel Nicolaus | Analyst unavailable | $500 | $355.62 | -1.3% | Jun 24, 2022 |
| Goldman Sachs | Analyst unavailable | $530 | $357.33 | +4.6% | May 19, 2022 |
| Barclays | Balaji Prasad | $700 | $364.5 | +38.2% | May 6, 2022 |
Track every rating change on IDXX the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationIDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments. For companion animals, IDEXX offers a comprehensive suite of point-of-care veterinary diagnostic tools, such as instruments, consumables, and rapid assay kits. It also provides reference laboratory diagnostic and consultation services, alongside practice management and diagnostic imaging solutions for veterinarians. Furthermore, the company supports the biomedical research community with health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services.…
Historical context
All IDXX earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| COO The Cooper Companies, Inc. | FY2026 Q3 · Calendar Q3 2026 | +2.7% | -14.7% | CooperCompanies beats expectations as inventory reduction weighs on vision revenue |
| MDT Medtronic plc | FY2027 Q1 · Calendar Q3 2026 | +4.3% | +1.5% | Medtronic raises FY27 outlook as growth broadens across platforms |
Latest beats and misses
Who reports nextBeat on EPS
Get the IDXX recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-10-08T07:00:43.541003+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-08T07:00:43.537999+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-08. For educational purposes only; not investment advice.